New insider Amato Anthony N. claimed ownership of 558,202 shares (SEC Form 3)
$BSGM
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 04/30/2024 |
3. Issuer Name and Ticker or Trading Symbol
BioSig Technologies, Inc. [ BSGM ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock, $0.001 par value per share | 500,000(1) | D | |
| Common Stock, $0.001 par value per share | 50,000(2) | D | |
| Common Stock, $0.001 par value per share | 6,250(3) | D | |
| Common Stock, $0.001 par value per share | 1,952(4) | D | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Explanation of Responses: |
| 1. The shares of restricted stock were granted for services and were fully vested as of March 1, 2024, the date of the grant, based on a closing price of $0.705 per share. |
| 2. The shares of restricted stock were granted for services and were fully vested as of June 7, 2024, the date of the grant, based on a closing price of $1.865 per share. |
| 3. Consists of (i) 2,500 shares of restricted stock granted for services on January 5, 2021 with a cost basis of $39.90 that vested in equal quarterly installments over one year, and (ii) 3,750 shares of restricted stock units granted for services on June 26, 2023 with an average cost basis of $5.05 that vested in two equal quarterly installments. |
| 4. The shares of common stock were purchased in a private placement on March 12, 2019, based on a price of $40.00 per share. |
| Remarks: |
| Mr. Amato was appointed as chief executive officer of BioSig Technologies, Inc. on April 30, 2024. |
| /s/ Anthony Amato | 07/05/2024 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||